Janssen COVID-19 Vaccine

Product description

Brand name
Janssen COVID-19 Vaccine
Company name
Janssen Inc
Ad26.COV2.S [recombinant]
Authorized By Interim Order
Date of approval


Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.

Updated Date Resources for Resources Description Date
Consumers, Health Care Professionals

Information about the product including what the product is used for, dosage, warnings, proper use and side effects.  This summary will not tell you everything about the product. Contact your healthcare professional if you have any questions about the product.

Health Care Professionals, Researchers

The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.

The Product Monograph includes three sections:

  • Part I: Health Professional Information;
  • Part II: Scientific Information; and
  • Patient Medication Information
Health Care Professionals

Vial and carton labels for vaccine with English-only labelling. These labels are used for the initial supply of vaccine.


The Regulatory Decision Summary explains Health Canada’s decision for the product seeking market authorization. The Regulatory Decision Summary includes the purpose of the submission and the reason for the decision.

Health Care Professionals, Researchers

The Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.

Health Care Professionals, Researchers

The Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.

Health Care Professionals, Researchers

Health Product Risk Communications are published to inform healthcare professionals about issues that can include the safety, or effectiveness, of a health product. It is a communication issued by the market authorization holder containing content approved by Health Canada. The most recent communication can be found here. All Health Product Risk Communications are posted in Health Canada’s recalls and safety alerts database and can be found by clicking on the "Advisories" section.

Consumers, Health Care Professionals, Researchers

Information about adverse events following immunization. An adverse event is a medical incident that may occur following immunization. The cause is not necessarily related to the vaccine.

Health Care Professionals, Researchers

The Company’s Risk Management Plan describes:

  • Known and potential safety issues
  • The company’s monitoring plan, including plans for collection of additional safety and effectiveness information
  • Any measures that will be put in place to minimize risks associated with the product.

After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.

Health Care Professionals, Researchers

For COVID-19 authorizations, Health Canada can impose specific terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and/or quality of the product as more studies are completed.

Consumers, Health Care Professionals, Researchers

Advisories are published when Health Canada has important updates or other information to share about the product, such as information on shortages, new approvals, or risks.

Clicking the link will retrieve any advisories Health Canada has issued about the product. If no advisories have been issued, no results will be returned.